Related references
Note: Only part of the references are listed.First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays
Sebastien Boulo et al.
ALZHEIMERS & DEMENTIA (2020)
Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years
Suzanne E. Schindler et al.
ALZHEIMERS & DEMENTIA (2018)
Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results
Betty M. Tijms et al.
CLINICAL CHEMISTRY (2018)
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Anja Hviid Simonsen et al.
ALZHEIMERS & DEMENTIA (2017)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Failure of Current Laboratory Protocols to Detect Lot-to-Lot Reagent Differences: Findings and Possible Solutions
Alicia Algeciras-Schimnich et al.
CLINICAL CHEMISTRY (2013)
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update
Marta del Campo et al.
BIOMARKERS IN MEDICINE (2012)
Age and diagnostic performance of Alzheimer disease CSF biomarkers
N. Mattsson et al.
NEUROLOGY (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Share Paper
